<DOC>
	<DOCNO>NCT00957580</DOCNO>
	<brief_summary>This open-label , multi-center , dose-escalation trial pimasertib ( MSC1936369B ) blood bone marrow cancer . The trial conduct two part : Part 1 ( safety run-in period ) : Will determine maximum tolerate dose ( MTD ) study drug subject advance hematological malignancy . Part 2 : Will assess anti-leukemic activity study drug old subject newly diagnose poor prognosis acute myeloid leukemia ( AML ) candidate intensive chemotherapy .</brief_summary>
	<brief_title>Trial Pimasertib Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion criterion : Part 1 : 1 . Subjects one follow condition : Primary secondary AML , pathologically confirm accord World Health Organization ( WHO ) classification meet least one follow condition : 1 . Subjects second subsequent relapse standard therapy , establish treatment option available 2 . Subjects refractory available therapy , example , fail achieve complete response ( CR ) 2 induction chemotherapy treatment 3 . Newlydiagnosed old subject ( great equal 75 year age ) , candidate intensive chemotherapy Subjects myelodysplastic syndrome ( MDS ) , International Prognostic Scoring System ( IPSS ) Int2 high risk resistant intolerant standard treatment candidate transplantation Subjects relapse refractory multiple myeloma ( MM ) , fail intolerant least two prior therapy include thalidomide , lenalidomide bortezomib Subjects advance myeloproliferative disorder ( MPD ) establish treatment option available Subjects acute lymphocytic leukemia ( ALL ) , relapse , refractory intolerant standard treatment effective treatment option available 2 . Age great equal 18 year 3 . Subjects read understood Informed Consent Form willing able give inform consent . They fully understand requirement trial willing comply trial visit assessment 4 . Subjects partner must willing avoid pregnancy trial 1 month last trial drug administration . Subjects must therefore willing use adequate contraception approve Investigator , two barrier method one barrier method spermicide intrauterine device , 2 week , trial 1 month . The use hormonal contraceptive avoid due possible drugdrug interaction female subject childbearing age Part 2 : 1 . Subjects ( male female ) newly diagnose primary secondary AML pathologically confirm accord WHO classification expose prior therapy AML exception : Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea allow 24 hour start trial treatment . Prior therapy preexist hematological condition , example , MDS MPD , include limited hypomethylating agent , also allow least 2 week 5 halflives agent first dose pimasertib 2 . Subjects meet least one follow condition : Age great equal 75 year OR Age great equal 60 less 75 year least one follow poor prognostic factor : Secondary AML , determine know documented exposure leukemogenic therapy environmental toxin antecedent history MDS MPD accord WHO criteria least 3 month prior trial entry , prior bone marrow aspirate , biopsy peripheral blood smear document diagnosis At least one follow unfavorable cytogenetic abnormality : del ( 5q ) , 5 , 7 , del ( 7q ) , abn 3q , 9q , 11q , 20q , 21q , 17p , ( 6 ; 9 ) , ( 9 ; 22 ) complex karyotype ( great equal 3 unrelated abnormality ) Eastern Cooperative Oncology Group ( ECOG ) status 2 3 . Subjects read understood Informed Consent Form willing able give inform consent . They fully understand requirement trial willing comply trial visit assessment 4 . Subjects partner must willing avoid pregnancy trial 1 month last trial drug administration . Subjects must therefore willing use adequate contraception approve Investigator two barrier method one barrier method spermicide intrauterine device , 2 week , trial 1 month . The use hormonal contraceptive avoid due possible drugdrug interaction female subject childbearing age Part 1 Part 2 : 1 . ECOG performance status 3 great 2 . Hyperleukocytosis great 30 x 10 ninth power per liter leukemia blast peripheral blood 3 . Acute promyelocytic leukemia [ ( 15 ; 17 ) ] 4 . Administration antineoplastic therapy within least 2 week 5 half life therapy first pimasertib dose ; except use hydroxyurea permit inclusion criterion 5 . Participation clinical trial within least 2 week first pimasertib dose 6 . Clinical evidence active central nervous system leukemia 7 . Active uncontrolled infection include limited know infection human immunodeficiency virus ( HIV ) , active hepatitis B hepatitis C. Subjects infection receive treatment antibiotic may enter trial afebrile hemodynamically stable 48 hour prior trial entry 8 . Major surgery within two week prior trial entry 9 . Liver function test follow limit screen : total bilirubin &gt; 1.5 x upper limit normal ( ULN ) unless relate Gilbert 's syndrome hemolysis , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x ULN , subject liver involvement AST and/or ALT &gt; 5 x ULN 10 . Serum creatinine &gt; 1.5 x ULN /or creatinine clearance &lt; 30 milliliter per minute ( mL/min ) screen 11. International normalize ratio ( INR ) great 1.5 x ULN unless treatment warfarin 12 . For female subject : pregnant breastfeed 13 . History difficulty swallowing , malabsorption chronic gastrointestinal disease condition may hamper compliance and/or absorption test product 14 . Has significant cardiac conduction abnormality and/or pacemaker 15 . Has retinal degenerative disease ( heredity retinal degeneration agerelated macular degeneration ) , history uveitis history retinal vein occlusion and/or medically relevant abnormal finding initial ophthalmologic examination 16 . Subjects solid tumor , Investigator clinical suspicion active disease time enrolment . Subjects adequately treat early stage squamous cell carcinoma skin , basal cell carcinoma skin , cervical intraepithelial neoplasia ( CIN ) eligible study 17 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) 18 . Other significant disease Investigator 's opinion would exclude subject trial 19 . Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEK Inhibitor</keyword>
	<keyword>Pimasertib</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Elderly Patients</keyword>
	<keyword>Phase II</keyword>
</DOC>